Filtered By:
Condition: Atrial Fibrillation
Management: Economics

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 62 results found since Jan 2013.

The IMPact of UntReated NOn-Valvular Atrial Fibrillation on Short-TErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model
CONCLUSION: Our findings suggest that increased overall OAC use has a positive clinical benefit on the annual number of ischemic stroke events and deaths avoided in the Medicare population, while maintaining a modest increase in the overall BI to the Medicare system.PMID:34415229 | DOI:10.1080/13696998.2021.1970954
Source: Journal of Medical Economics - August 20, 2021 Category: Health Management Authors: Matthew Sussman Manuela Di Fusco Charles Y Tao Jennifer D Guo John A Gillespie Mauricio Ferri Nicholas Adair Matthew S Cato Ilnaz Shirkhorshidian Geoffrey D Barnes Source Type: research

Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation
Conclusions Real-world Canadian data and a phase-based costing approach were used to estimate short- and long-term costs associated with AF-related major clinical events. The results of this study can also inform decision–analytic models for AF.
Source: Applied Health Economics and Health Policy - February 29, 2016 Category: Health Management Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. ...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
ConclusionsHCRU and most event-related costs were lower in patients initiating apixaban compared to other OACs. Apixaban may be cost-saving compared to VKAs, and significantly cheaper than other DOACs, although cost differences are limited.
Source: The European Journal of Health Economics - August 28, 2022 Category: Health Management Source Type: research

Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: the case study of Japan.
CONCLUSIONS: Introducing rivaroxaban may decrease the burden of NVAF in Japanese society. From a clinical perspective, the reduction in IS and embolic events outweighs the increased risk of anticoagulant-related bleeding; from an economic perspective, reduced event costs offset drug and physician visit costs, resulting in cost savings. PMID: 27112188 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 27, 2016 Category: Health Management Tags: J Med Econ Source Type: research

A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
ConclusionsThe modelling demonstrates the health benefits and economic effects of an implementation of a systematic screening on AF with “Preventicus Heartbeats”, given the perspective of the German payer, the statutory health care system.
Source: Health Economics Review - June 8, 2020 Category: International Medicine & Public Health Source Type: research

Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization
CONCLUSION: Patients with PAD who experience major atherothrombotic vascular events post-revascularization have considerably higher healthcare resource use and costs compared with similar metrics pre-revascularization. Therefore, reducing the rate of such events could reduce overall healthcare costs for this population.PMID:33634723 | DOI:10.1080/13696998.2021.1891089
Source: Journal of Medical Economics - February 26, 2021 Category: Health Management Authors: Urvi Desai Akshay Kharat Connie N Hess Dejan Milentijevic Fran çois Laliberté Peter Zuckerman John Benson Patrick Lefebvre William R Hiatt Marc P Bonaca Source Type: research

Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries
ConclusionThe model results showed a strong dependence of the results on the country-specific costs for stroke treatment. The use of the investigated screening method is close to cost-neutral or cost-reducing in the Western European countries and Greece. In countries with low price levels, higher cost increases due to AF screening are to be expected. Lower costs of anticoagulation, which are expected due to the upcoming patent expiry of direct anticoagulants, have a positive effect on the cost result.
Source: Health Economics Review - February 26, 2022 Category: International Medicine & Public Health Source Type: research